# lung adenocarcinoma (LUAD) - grok-4.6

- Benchmark system: E2seq + Agent RAG
- Repeat: 7
- Task type: PROGNOSIS
- Tissue / sample source: lung adenocarcinoma tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: xAI / grok-4.6
- Message SHA-256: a2c9355177479f23c6c81afe1b39ba697ac131cc344bb83120b98e2c6bbfee49
- Response HTTP status: 200
- Prompt tokens: 45628
- Completion tokens: 16534
- Reasoning tokens: 11829
- Total tokens: 62162
- API requests reported: 3
- Elapsed seconds: 117.962
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 957.651
- Question handoff seconds: 970.897
- Final benchmark system: E2seq; file rank 5/5; original repeat 7; model vendor: xAI

---
**Overall biological interpretation**  
The prognostic results from LUAD tumor tissue reveal a highly significant risk signature for poor overall survival, dominated by non-coding RNAs and pseudogenes with extreme hazard ratios, alongside a small protective component. Although many HR magnitudes raise statistical concerns, the annotated genes align with the analysis selection for dysregulation of Wnt signaling, glycosphingolipid biosynthesis, planar cell polarity, and cell junction disassembly. This points to membrane remodeling, motility, polarity defects, and adhesion loss as plausible contributors to aggressive disease behavior and worse OS.

**Core biological programs**  
1. **Regulation of Wnt signaling pathway (risk-associated)**  
   Major supporting genes: DKK1.  
   The most appropriate standardized pathway: Wnt signaling pathway (KEGG).  
   The gene DKK1 indicates dysregulated Wnt activity that can promote proliferation or metastasis in LUAD, consistent with the selected GO terms for regulation and positive regulation of Wnt signaling.  
   Strength of the evidence: low; major limitations: single gene in the cohort, no formal enrichment or replication statistic, potential single-gene artifact.

2. **Glycosphingolipid biosynthesis (risk-associated)**  
   Major supporting genes: FUT4, CMAHP.  
   The most appropriate standardized pathway: Glycosphingolipid biosynthesis (KEGG).  
   These genes support membrane lipid remodeling that influences adhesion and signaling; FUT4 risk association contrasts with CMAHP protective effect, collectively suggesting opposing roles in glycosphingolipid metabolism during tumor progression, matching the selected KEGG term.  
   Strength of the evidence: low; major limitations: mixed directionality, only two genes, limited annotation.

3. **Planar cell polarity pathway (risk-associated)**  
   Major supporting gene: RHOF.  
   The most appropriate standardized pathway: Planar Cell Polarity Pathway (GO:2000096).  
   RHOF supports actin filament organization and cell migration, consistent with the selected GO term and indicating polarity defects that may drive LUAD metastasis.  
   Strength of the evidence: low; major limitations: single gene in the cohort, no additional supporting genes or pathway co-membership in the batch.

4. **Cell junction disassembly (risk-associated)**  
   Major supporting gene: LDLRAD3.  
   The most appropriate standardized pathway: Cell Junction Disassembly (GO:0150146).  
   LDLRAD3 risk association supports junction breakdown that promotes invasion and metastatic dissemination in LUAD, aligning with the selected GO term.  
   Strength of the evidence: low; major limitations: single gene in the cohort, no multiple independent genes or formal enrichment.

**Key genes and interaction modules**  
- **RHOF** (risk-associated, HR = 1.403): Planar cell polarity program; direct physical interaction with ACTN1 (STRING evidence).  
- **KRT6A** (risk-associated, HR = 1.390): Cytoskeletal/polarity program; pathway co-membership with RHOF.  
- **DKK1** (risk-associated, HR = 1.475): Wnt program; regulatory interaction with β-catenin (external annotation).  
- **FUT4** (risk-associated, HR = 1.403): Glycosphingolipid program; co-membership with CMAHP.  
- **CMAHP** (protective-associated, HR = 0.705): Glycosphingolipid program; co-membership with FUT4.  
- **RGS20** (risk-associated, HR = 1.352): GPCR signaling; direct physical interaction with GNAZ and GNB5 (STRING evidence).  
- **LDLRAD3** (risk-associated, HR = 1.420): Cell junction program; indirect or putative relationship with APP (STRING evidence).  
- **CRNDE** (protective-associated, HR = 0.716): Regulatory lncRNA network; regulatory interaction in proliferation pathways.  
- **ITGB1-DT** (risk-associated, HR = 1.302): Regulatory lncRNA; putative regulatory interaction with ARNTL2 (literature-supported axis).  
- **TLE1** (risk-associated, HR = 1.484): Transcriptional regulation; regulatory interaction with PITX3.

**Validation priorities**  
- **Mechanistic hypothesis**: RHOF-driven polarity and actin remodeling in LUAD metastasis. Why it deserves prioritization: risk HR, alignment with selected Planar Cell Polarity Pathway, and established Rho-family roles in migration. Evidence provided by current dataset: HR and FDR. External evidence supports plausibility (literature on RhoF in other cancers); no contradiction. Most appropriate next step: CRISPR knockdown in LUAD cell lines followed by polarity and invasion assays. Status: supported hypothesis.  
- **Biomarker**: DKK1 for OS stratification. Why it deserves prioritization: risk HR and Wnt pathway relevance. Evidence provided by current dataset: HR and FDR. External evidence includes multiple cancer studies linking DKK1 to survival (supports; no conflict). Most appropriate next step: RT-qPCR validation in independent LUAD cohort with OS correlation. Status: supported hypothesis.  
- **Interaction / network hypothesis**: RGS20–G-protein complex in LUAD proliferation. Why it deserves prioritization: STRING direct interactions plus Reactome pathway membership. Evidence provided by current dataset: HR and FDR. External evidence: protein–protein interaction records (supports). Most appropriate next step: co-immunoprecipitation to test physical binding. Status: exploratory hypothesis.  
- **Confounding or composition check**: Tumor-purity effects on lncRNA/pseudogene signals. Why it deserves prioritization: extreme HR distribution in 96 non-coding genes. Evidence provided by current dataset: HR magnitudes and FDR distribution. External evidence: TCGA purity metrics available (supports plausibility). Most appropriate next step: re-analysis with ESTIMATE or CIBERSORT adjustment. Status: exploratory.  
- **Biomarker**: KRT6A as epithelial-mesenchymal transition marker. Why it deserves prioritization: risk HR and known cytoskeletal role in carcinomas. Evidence provided by current dataset: HR and FDR. External evidence: literature on KRT6A in epithelial cancers (supports). Most appropriate next step: IHC validation in tumor tissue microarrays. Status: supported hypothesis.

**Evidence grounding**  
All HR, P, and FDR values constitute the sole direct statistical evidence from the input dataset and statistical ledger. Pathway/ontology evidence (KEGG, GO) derives from the question-time batch selections for the programs above. Protein interaction/regulatory evidence (STRING) is available for RHOF, RGS20, LDLRAD3, and related partners. Disease-association and expression evidence (GTEx, literature) contextualizes individual genes but does not replace the cohort statistics. No independent-cohort HR, FDR, or replication statistic is supplied for any gene or program; all external records are single-cohort or annotation-based and may derive from overlapping publication sources. No conflicting evidence is present.

**Limitations and alternative explanations**  
- Extremely high HR values (many > 10²¹) with P = 0 may reflect statistical instability from few overall-survival events rather than true effect size; distinguishable by bootstrap resampling, event-count stratification, or exclusion of genes with P = 0.  
- Predominance of unannotated lncRNAs/pseudogenes prevents robust program-level inference beyond the small annotated subset; functional annotation and experimental validation required.  
- Potential tumor-purity or stromal-composition effects on non-coding signals; distinguishable by correlating HRs with ESTIMATE scores or pathological purity estimates.  
- Association-versus-causation ambiguity; experimental knockdown or CRISPR studies are required to test direct contributions.  
- Absence of replication data; any program signal remains exploratory and requires independent-cohort confirmation.  

The transcriptomic prognostic analysis in LUAD identifies a significant risk signature predominantly driven by non-coding elements, with exploratory biological programs centered on Wnt signaling, glycosphingolipid metabolism, planar cell polarity, and cell junction disassembly that warrant targeted experimental follow-up.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=10, external claims checked=0, external mismatches=0, status=passed.

Answer model API: xAI / grok-4.6

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 53/100 selected items (records returned); cbioportal 51/100 selected items (records returned); chembl 16/100 selected items (records returned); civic 1/100 selected items (records returned); clinicaltrials 6/100 selected items (records returned); clinvar 30/100 selected items (records returned); ensembl 11/100 selected items (partially returned; some queries failed); europepmc 362 articles / initial full-cohort RAG 100 queries + 4 current-round queries; some queries failed; gtex 81/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 14/100 selected items (records returned); humanbase 56/100 selected items (partially returned; some queries failed); intact 18/100 selected items (records returned); mygene 59/100 selected items (records returned); omnipath 3/100 selected items (records returned); opentargets 55/100 selected items (records returned); pubmed 202 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 17/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 17/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 2/100 selected items (records returned); string 14/100 selected items (records returned); trrust 4/100 selected items (records returned)
